BioTelemetry “executed beautifully on all fronts” in Q4 and during 2018 and its outlook for 2019 is strong, Lake Street analyst Brooks O’Neil tells investors in a post-earnings research note. The analyst believes remote patient monitoring is in its infancy and that BioTelemetry is the leader in this “exciting space.” He affirms his Buy rating on the shares with a $90 price target.
https://thefly.com/landingPageNews.php?id=2868659
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.